Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Myelodysplastic/Myeloproliferative Syndromes

Treosulfan + Fludarabine + TBI for Allo HCT for AML and MDS (FHCRC-2272)
Conditioning With Treosulfan, Fludarabine And Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Status Conditions Phase Study ID
Closed Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD)
Phase II FHCRC-2272
NCT00860574
Summary

The purpose of this study is to look at the effects, good or bad, of an experimental combination of low-dose total body irradiation (TBI) and chemotherapy drugs, given prior to stem-cell transplantation, in patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

The chemotherapy drugs used in this research study are treosulfan and fludarabine. These drugs will be given along with low-dose total body irradiation (TBI). Study participants will then undergo a donor bone-marrow or peripheral-blood stem-cell transplant.

Participants will receive treatment at the Seattle Cancer Care Alliance (SCCA) and at the University of Washington Medical Center (UWMC).

Treatment on this study will last about 3 ½ months. We would like to do long-term follow-up by calling each study participant on the telephone once a year to see how he or she is doing.


Investigator
Boglarka Gyurkocza, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)

1. Age 60 years or younger

2. Diagnosed with one of the following:

- Acute myeloid leukemia (AML) beyond 1st remission, or intermediate or high-risk AML in 1st complete remission

- Myelodysplastic syndrome (MDS)

3. A suitable donor is available

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

Prior or concurrent umbilical cord blood transplantation (prior autologous or allogeneic hematopoietic stem cell transplantation is allowed)

Inadequate organ function (heart, lung, kidney, liver) 

Active infectious disease, HIV-positivity, or active infectious hepatitis

CNS leukemic involvement

Pregnant or lactating Other exclusion criteria may apply.

Last Updated
November 15, 2012
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.